SignalFDA/Bio

HUTCHMED JUMPS 15% AFTER LICENSING CANCER THERAPY TO GSK FOR UP TO $1.295B - SEEKINGALPHA

Licensing deal with GSK worth up to $1.295B drives 15% stock jump.

What changed

Licensing deal with GSK worth up to $1.295B drives 15% stock jump.

Why it matters

Licensing deal with GSK worth up to $1.295B drives 15% stock jump. — impact context not separately stored; see What changed.

Sources